ZOFENIL

This brand name is authorized in Austria, Germany, France, Ireland, Poland

Active ingredients

The drug ZOFENIL contains one active pharmaceutical ingredient (API):

1 Zofenopril UNII 88ZQ329PU2 - ZOFENOPRIL CALCIUM

The beneficial effects of zofenopril in hypertension and acute myocardial infarction appear to result primarily from the suppression of the plasma renin-angiotensin aldosterone system. Inhibition of ACE (Ki 0.4nM in rabbit lung for arginine salt of zofenoprilat) results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. Read about Zofenopril

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZOFENIL Film-coated tablet	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09AA15	Zofenopril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 09895725, 09895731
Country: FR	Base de données publique des médicaments	Identifier(s): 60780754, 62757373, 67049435
Country: IE	Health Products Regulatory Authority	Identifier(s): 53965, 53972
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100134571, 100134588, 100455699